Viability and Cardiac Resynchronization Therapy

Launched by UNIVERSITY HOSPITAL, GENTOFTE, COPENHAGEN · Aug 7, 2009

Keywords

ClinConnect Summary

Cardiac resynchronization therapy (CRT) is an established therapy for patients with severe heart failure, depressed left ventricular function and a wide QRS-complex. Large clinical trials have demonstrated unequivocal improvements in functional status, morbidity and mortality. However, 30 % of heart failure patients treated with a CRT-device do not benefit clinically. Several factors have been suggested to be important for the response to CRT such as mechanical dyssynchrony, presence of scar tissue in the myocardium, and device-optimization (among others). It is the purpose of this study to...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • LVEF\</= 35%, QRS-duration\>/= 120 ms, NYHA-class II- IV.
• • Ischemic heart disease (\> 50% stenosis in 1 or more major epicardial coronary artery or prior PCI or CABG.)
• • Optimal treatment ( beta-blocker, ACE-1 or ARB and spironolactone)
• Exclusion Criteria:
• • Pregnancy
• • Unstable angina pectoris
• • Chronical atrial fibrillation
• • Severe valvular disease
• • Dementia or mental retardation
• • Severe claustrophobia
• • Acute myocardial infarction \< 3 months
• • Severe health condition threatening short-term survival
• • Severe kidney insufficiency, GFR \< 35 ml/min/1.73 m2
• • Metal implants contraindicative of magnetic resonance scan